A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

• Published in: Cancer gene therapy Vol. 14; no. 11; pp. 885 - 893
• Main Authors: Nemunaitis, J, Senzer, N, Sarmiento, S, Zhang, Y-A, Arzaga, R, Sands, B, Maples, P, Tong, A W
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01-11-2007
• Subjects: Adenoviridae; Adenovirus; Adenoviruses; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cancer; Carcinoma; Carcinoma - drug therapy; Deoxyribonucleic acid; DNA; Dosage; Drug therapy; Etanercept; Female; Genetic aspects; Health aspects; Humans; Immunoglobulin G - administration & dosage; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Infusions, Intravenous; Intravenous administration; Male; Middle Aged; Oncolysis; Receptors, Tumor Necrosis Factor - administration & dosage; Receptors, Tumor Necrosis Factor - therapeutic use; Solid tumors; Tumor cells; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - blood; Tumor necrosis factor-α; Viral Vaccines; United States
• ISSN: 0929-1903; 1476-5500
• DOI: 10.1038/sj.cgt.7701080

ONYX-015 is an attenuated chimeric human group C adenovirus, which preferentially replicates in and lyses tumor cells that are p53 negative. The purpose of this phase I, dose-escalation study was to determine the safety and feasibility of intravenous infusion with ONYX-015 in combination with enbrel in patients with advanced carcinoma. Enbrel is a recombinant dimer of human tumor-necrosis factor (TNF)-alpha receptor, previously shown to reduce the level of functional TNF. Nine patients, three in each cohort received multiple cycles of ONYX-015 infusion (1 x 10(10), 1 x 10(11) and 1 x 10(12) vp weekly for 4 weeks/cycle) in addition to subcutaneous enbrel (only during cycle 1) injections per FDA-indicated dosing. Of the nine patients, four had stable disease. No significant adverse events were attributed to the experimental regimen, confirming that enbrel can be safely administered along with oncolytic virotherapy. Two of the three patients in cohort 3 had detectable viral DNA at days 3 and 8 post-ONYX-015 infusion. Their detectable circulating viral DNA was markedly higher during cycle 1 (with enbrel coadministration) as compared with cycle 2 (without enbrel) at the same time points. Area under the curve determinations indicate a marked higher level of TNF-alpha induction and accelerated clearance at cycle 2 in the absence of enbrel. Further assessment is recommended.